Zhejiang Jingxin Pharmaceutical sees mixed Q3, net profit up 8.59%

Zhejiang Jingxin Pharmaceutical Co., Ltd. announced its Q3 2025 results, showing a 2.57% decrease in operating revenue to 1,031,649,329.24 yuan for the quarter. Net profit attributable to shareholders increased by 8.59% to 187,732,848.96 yuan. Year-to-date, operating revenue fell 5.00% to 3,048,192,079.46 yuan, with net profit attributable to shareholders seeing a slight 0.10% rise to 575,611,846.06 yuan. Basic and diluted earnings per share both increased by 15.00% to 0.23 yuan for the quarter.

The company's total assets decreased by 5.90% to 7,978,648,630.10 yuan by the end of the reporting period, and net assets attributable to shareholders declined by 5.33% to 5,651,372,562.72 yuan. Significant changes in assets include a 43.01% increase in monetary funds due to reduced investment expenditure, and a 74.56% decrease in transactional financial assets as a result of reduced wealth management purchases.

Zhejiang Jingxin Pharmaceutical also reported engaging in a share buyback program, repurchasing 47.271295 million shares, accounting for 5.49% of its total share capital, at a total cost of 608.7222 million yuan. Additionally, a fourth phase of its employee stock ownership plan was approved, aiming to raise up to 150 million yuan to purchase 12 million of the repurchased shares.